MindBio Therapeutics Corp. (WF6.F)
| Previous close | 0.0326 |
| Open | 0.0352 |
| Bid | 0.0398 x N/A |
| Ask | 0.0452 x N/A |
| Day's range | 0.0352 - 0.0352 |
| 52-week range | 0.0088 - 0.1080 |
| Volume | |
| Avg. volume | 6,950 |
| Market cap | 6.355M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireInvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression
VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for mental health conditions, has initiated dosing of MB22001 to patients in a landmark microdosing study for depression. This groundbreaking trial represents a global precedent and stands as the sole clinical trial authorized for the take-home usage of LSD. A Media Snippet accompanying this announcement is a
- GlobeNewswire
InvestmentPitch Media Video Discusses MindBio Therapeutics’ Clinical Trials of LSD-Microdosing Reveals Significant Positive Impact on Quality of Sleep
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, announced a significant breakthrough based on sleep data collected during randomized controlled trials of LSD-Microdosing. The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed. A Media Snippet accompanying this announcement is available by clicking on the image or link below: For
- GlobeNewswire
InvestmentPitch Media Video Discusses MindBio Therapeutics’ Receipt of Initial Shipment of 1,000,000 Microdoses of LSD for Phase 2 Clinical Trials for Depression
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, received its initial microdoses of LSD. MindBio announced that its initial delivery of 1,000,000 microdoses of LSD had arrived at its labs, following a secure chain of custody, for process in preparation for two separate Phase 2 take home LSD-Microdosing Clinical Trials, which are both fully funded. This LSD will be use
